Search

Your search keyword '"Schwartz, Gregory G"' showing total 948 results

Search Constraints

Start Over You searched for: Author "Schwartz, Gregory G" Remove constraint Author: "Schwartz, Gregory G"
948 results on '"Schwartz, Gregory G"'

Search Results

153. Alirocumab after acute coronary syndrome in patients with a history of heart failure.

155. Contributing Authors

156. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

158. Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program

159. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes

160. Abstract 332: Racial Differences in Prescribing of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Among Veterans With Type 2 Diabetes and Coronary Artery Disease: Findings From the Veteran’s Administration Clinical Assessment, Reporting, and Tracking Program

161. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

162. APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL

163. ACHIEVEMENT OF NEW EUROPEAN DYSLIPIDEMIA-GUIDELINE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TREATMENT GOALS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM ODYSSEY OUTCOMES

164. ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS

165. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial

166. POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM

167. EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL

168. ELIGIBILITY FOR AND USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN VETERANS WITH TYPE 2 DIABETES AND CORONARY ARTERY DISEASE: PROSPECTIVE ANALYSIS FROM THE CARDIAC CATHETERIZATION LAB CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM

170. Reply

171. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

172. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

174. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome:ODYSSEY OUTCOMES Trial

175. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

176. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

177. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

179. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome

180. Transesophageal echocardiography in rats using an intravascular ultrasound catheter

184. Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

187. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

188. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

189. Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial

190. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.

191. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.

192. ALP Levels Predict Adverse Cardiovascular Outcomes and Cognitive Impairment in High Risk Patients

193. Effect of alirocumab on mortality after acute coronary syndromes : an analysis of the ODYSSEY OUTCOMES randomized clinical trial

194. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial

195. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.

198. Inhibition of fatty acid metabolism alters myocardial high-energy phosphates in vivo

199. Relation among regional O2 consumption, high-energy phosphates, and substrate uptake in porcine right ventricle

200. Atorvastatin for Acute Coronary Syndromes

Catalog

Books, media, physical & digital resources